To compare the effect of tacrolimus and pimecrolimus in white patch patients

To compare the efficacy of topical 0.1% tacrolimus ointment and pimecrolimus 1% cream in Vitiligo.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2014/08/004882

Enrollment

Registered

2014-08-14

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Vitiligo

Interventions

Intervention1: Tacrolimus 0.1% ointment: Over the vitiligo patch twice daily for 6 months Control Intervention1: Pimecrolimus 1 % cream: Over the vitiligo patch twice daily for 6 months

Eligibility

Inclusion criteria

Inclusion criteria: Less than 20 % body surface area involvement in patients with vitiligo Patients having vitiligo not on any other treatment for last 4 weeks

Exclusion criteria

Exclusion criteria: Involvement of more than 20% body surface area in patients with vitiligo Immunocompromised patients History of skin cancers or lymph proliferative disorders Pregnant or lactating women Patients on any other treatment for last 4 weeks Netherton syndrome Drop outs from the study

Design outcomes

Primary

Measure	Time frame
To compare the efficacy of topical tacrolimus 0.1% ointment and pimecrolimus 1% cream in vitiligo patientsTimepoint: To compare the efficacy of topical tacrolimus 0.1% ointment and pimecrolimus 1% cream in vitiligo patients	—

Secondary

Measure	Time frame
To compare the safety of Tacrolimus 0.1% ointment and Pimecrolimus 1 %cream in vitiligoTimepoint: 6 months	—

Countries

India

Contacts

Public ContactTANVI SINGH BHADORIA

Peoples college of medical sciences

colnelms@yahoo.com9591711114

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026